Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial
1. 系统已在2025-06-23 09:36:35对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/s2213-8587(24)00313-9
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S2213858724003139
其他信息:
出版社: Elsevier BV
作者: Frederick J Raal; Vimal Mehta; Meral Kayikcioglu; Dirk Blom; Preeti Gupta; Avishay Elis; Traci Turner; Chris Daniels; Jeffrey Vest; Tracy Mitchell; Kate Caldwell; El Mustapha Bahassi; David Kallend; Evan A Stein